



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

LORI L. KERBER
INCYTE CORPORATION
3160 PORTER DRIVE
PALO ALTO, CALIFORNIA 94304

In re Application of :
Tang et al. :Petition to Review Lack of Unity
Serial No: 09/700,590 :Under 37 C.F.R. 1.144
Filed: 16 April 2001 :
Attorney Docket No: PF-0526 USN :

This is in response to applicant's petition under 37 CFR 1.144, filed 29 March 2004, requesting review of the Examiner's lack of unity requirement mailed 25 July 2001.

BACKGROUND

This application is a U.S. national stage application properly filed under 35 USC 371.

The Examiner instituted a lack of unity requirement of claims 1-20 into 8 groups and required a selection of a single sequence for examination in an Office action which was subsequently made final. In particular, the following lack of unity between Group II and Group I is at issue:

Group I, claims 1,2, 15, drawn to polypeptide having SEQ ID NO:101.

Group II, claims 3, 6, 9-14, drawn to polynucleotide encoding SEQ ID NO:101 or having SEQ ID NO 22.

In the response dated 23 December 2003 to the lack of unity requirement Applicant elected, with traverse, Group II and polynucleotides encoding polypeptide SEQ ID NO:101 including the nucleotide SEQ ID NO:22. The examiner then considered the traversal, found it not persuasive and made the lack of unity holding final.

RELEVANT AUTHORITY

An international or a national stage application are considered to have unity of invention where there exists a “special technical feature” that defines a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. See PCT Rule 13.2; 37 CFR 1.475(a), (b)(1) and (2).

PCT Rule 13.2 Circumstances in Which the Requirement of Unity of Invention Is to Be Considered Fulfilled

Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression “special technical features” shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

PCT Administrative Instructions, Annex B, Part 2, Example 17 states:

Claim 1: Protein X

Claim 2: DNA sequence encoding protein X.

Expression of the DNA sequence in a host results in the production of a protein which is determined by the DNA sequence. The protein and the DNA sequence exhibit corresponding special technical features. Unity of invention between claims 1 and 2 is accepted.

Unity of invention has to be considered in the first place only in relation to the independent claims in an international application and not the dependent claims.

DISCUSSION

Applicant's petition and the file record have been carefully considered.

Applicants are correct that the above-identified application is a national stage application submitted under 35 U.S.C. 371 to which “unity of invention”, and not U.S. restriction practice is applicable. See MPEP section 1893.03(d). The lack of unity between independent polypeptide claims of Group I and independent polynucleotide claims of Group II is therefore at issue.

Independent claim 21 (corresponding to Group I) and claim 31 (corresponding to Group II) are reproduced below:

21. An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:22,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:22,

- c) a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:22, and
- d) an immunologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:22, wherein said immunologically active fragment generates an antibody that specifically binds to SEQ ID NO:22.

31. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:101,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to the polynucleotide sequence of SEQ ID NO:101,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

Applicant argues that in accordance with PCT Administrative Instructions, Example 17, the claims of Group I and Group II should possess unity of invention. Applicants have argued and added emphasis to the following sentence of Example 17:

The protein and the DNA sequence exhibit corresponding special technical features.

Applicants appear to be arguing that this sentence is a conclusion directed at any particular combination of DNA and protein inventions. This is not persuasive. This sentence is understood to present background facts relating to this particular example which specifies that in these claims, the DNA encodes the protein, the DNA and protein make a contribution over the prior art. In the inventions of Example 17, the groups share a technical feature which makes a contribution over the prior art, therefore, unity is accepted.

Applicant's argument is misplaced since PCT Rule 13.2 and Example 17 specifically indicates that unity of invention between the protein and its corresponding encoding nucleotide sequence requires that the protein and the DNA sequence exhibit corresponding special technical features, i.e., make a contribution over the prior art.

The inventions under consideration here do not fit into the pattern of Example 17 and therefore are not considered to have unity of invention for the following reasons. It is first noted that the representative claims 21 and 31 above are drawn to a genus of nucleotides encoding a genus of polypeptides and not a genus of nucleotides encoding a single protein as in Example 17. Accordingly, in the first instance, unity of invention pursuant to Example 17 may not be applicable.

With regard to the isolated polynucleotides of claim 31, it is first noted these polynucleotides lack the functional limitation required by Example 17 since the polynucleotides of claim 31 are not required to encode any polypeptide. Claim 31(b) defines the polynucleotide only in terms of partial structure and reads upon polynucleotides which are at least 90% identical to SEQ ID NO:101. A polynucleotide containing a stop codon truncating the open reading frame or the presence of a splice site which results in an open reading frame shift would fit into the required structural limitation but it would not encode the polypeptide having at least 90% identity to SEQ

ID NO:22. The complementary sequences encompassed by parts (c) and (d) of claim 31 are non-coding strands of any length. Transcription and translation of a non-coding strand would not result in the polypeptide having SEQ ID No 22. Within the large numbers of polynucleotides encompassed by Claim 31, many which could encode a polypeptide would not encode the polypeptides of Group I. For these reasons, Groups I and II lack a same or corresponding technical feature, as required by PCT Rule 13.2. The protein invention and the polynucleotide invention lack a one-to-one correspondence.

Even if the polynucleotides and polypeptides shared a same or corresponding technical feature, they do not both make a contribution over the prior art. The attached sequence alignment shows a polypeptide sequence which is 99.7 % identical to SEQ ID NO 22. See the alignment of SEQ ID NO 22 with Accession Number Y12059, submitted to Genbank on 2 May 1998, which is prior to the earliest claimed priority date of 29 May 1998. Claim 21, part (b) encompasses polypeptides which are 90% identical to SEQ ID No 22.

For these reasons, the lack of unity of invention between the polypeptide and the polynucleotide is maintained.

DECISION

Applicant's petition to withdraw the lack of unity requirement between Groups I and II under 37 CFR 1.144 is DENIED for the reasons set forth above.

The application will be forwarded to the Examiner for consideration of the Appeal Brief filed on 8 April 2004

Any request for consideration must be filed within two (2) months of the mailing date of this decision.

Should there be any questions regarding this decision, please contact Special Program Examiner Julie Burke, by mail addressed to Director, Technology Center 1600, PO BOX 1450, ALEXANDRIA, VA 22313-1450, or by telephone at (571) 272-1600.

Jasemine Chambers
Jasemine Chambers
Director, Technology Center 1600.



CGCTCAGGATAGACTTCGGCCGTAGAGATCGGATCCCCGGCGCTATTATAAGCTCGATCGATCTTCTTATCGCGATATGTTATACACACACCTCGGGCATAGCATGACTGATCTGCCAATTCCTTGCTTCTGCATAGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCACAGACCTACGGCTACCTACTTAACCAATCGGGAGGGGGCGGATCGCCCGAG

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	Books
Search	<u>Nucleotide</u>	<input checked="" type="checkbox"/> for					<input type="button" value="Go"/>	<input type="button" value="Clear"/>
			Limits	Preview/Index	History	Clipboard	Details	
Display	default	<input checked="" type="checkbox"/>	Show: 20	<input type="checkbox"/>	Send to	File	<input checked="" type="checkbox"/>	Get Subsequence

1: Y12059. H.sapiens HUNKI m...[gi:3115203]

Links

LOCUS HSHUNKI 3149 bp mRNA linear PRI 02-MAY-1998
 DEFINITION H.sapiens HUNKI mRNA.
 ACCESSION Y12059
 VERSION Y12059.1 GI:3115203
 KEYWORDS HUNKI gene.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Weber, B.
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 3149)
 AUTHORS Weber, B.
 TITLE Direct Submission
 JOURNAL Submitted (24-MAR-1997) B. Weber, Labor Paediatrische
 Molekularbiologie, Universitaetsklinikum Charite, Ziegelstr. 5-9,
 10098 Berlin, FRG
 FEATURES Location/Qualifiers
 source 1..3149
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /tissue_type="placenta"
 gene 1..3149
 /gene="HUNKI"
 CDS 223..2391
 /gene="HUNKI"
 /note="strong homology to human RING3 sequence"
 /codon_start=1
 /protein_id="CAA72780.1"
 /db_xref="GI:3115204"
 /db_xref="GOA:O60885"
 /db_xref="Swiss-Prot:O60885"
 /translation="MSAEGPGTRLRNLPVMGDLETSQMSTTQAQAPQPANAASTN
 PPPPETSNPKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKI
 TPMDMGTIKKRLENNYYWNAQECDIQCDFNTMFTNCYIYNKPGDDIVLMAEALEKLF
 LQKINELPTEETEIMIVQAKGRGRKRKETGTAKPGVSTVPTTQASTPPQTQTPQP
 NPPVQATPHPPPAVTPDLIVQTPVMTVVPQPLQTPPPVPPQPQPPPAPAPQP
 VQSHPPIIAATPQPVKKGKVKRKADTTPTTIDPIHEPPSLPPEPKTTKLGQR
 RESSRPVKPPKDVPPDSQQHPAPEKSSKVSEQLKCCSGILKEMFAKKHAAYAWPFY
 KPVDPVVAEGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVR
 LMFNSNCYKYNPPDHEVVAMARKLQDVFERMFAKMPDEPEEPV
 VAVSSPAVPPPTKVVAPPSSDSSSDSSSDSSTDSEEEERA
 QRLAELQEQLKAVHEQLAALSQPQQNPKKKKEKD
 KKEKKKEHKRKEEVEENKKS
 KAKEPPPKTKNNNSNSNVSKKEPAPMKS
 KPPPTYESEEEEDKCKPMS
 YEEKRQLSLDINKLPGEKLGRVVHIQSREPSLKNSNPDEIEIDF
 ETLKPSLTRELERYVT
 CLRKKRKPOAEKVDVIAGSSKMKGFSSESSESSSDSEDSETGP
 A"

ORIGIN

```

  1 attctttgga atactactgc tagaagtctg acttaagacc cagcttatgg gcccacatggc
  61 acccagctgc ttctgcagag aaggcaggcc actgatgggt acagcaaagt gtggtgctgc
  121 tggccaagcc aaagaccctgt gtaggatgac tggcctctg ccccttgtgg gtgttgcac
  181 tgtgctttag tgcctggta agaatgtgat gggatcacta gcatgtctgc ggagagcggc
  241 cctgggacga gattgagaaa tctgccagta atggggatg gactagaaac ttcccaaatg

```

301 tctacaacac aggcccaggc ccaaccccaag ccagccaacg cagccagcac caaccccccgg
361 cccccagaga cctccaaaccc taacaagccc aagaggcaga ccaaccaact gcaataacctg
421 ctcagagtgg tgctcaagac actatggaaa caccagttt catggcctt ccagcagcct
481 gtggatgcgg tcaagctgaa cctccctgtat tactataaga tcattaaaac gcctatggat
541 atgggaacaa taaagaagcg cttggaaaac aactattact ggaatgctca ggaatgtatc
601 caggacttca acactatgtt tacaatttgt tacatctaca acaagcctgg agatgacata
661 gtcttaatgg cagaagctct ggaaaagctc ttcttgcaaa aaataaatga gctacccaca
721 gaagaaaaccg agatcatgat agtccaggca aaaggaagag gacgtgggag gaaagaaaaca
781 gggacagcaa aacctggcgt ttccacggta ccaaacacaa ctcaagcattt gactcctccg
841 cagacccaga cccctcagcc gaatcctcctt cctgtgcagg coacgcctca ccccttcct
901 gccgtcaccc cggacctcat cggtcagacc cctgtcatga cagtggtgc tccccagcca
961 ctgcagacgc ccccgccagt gcccccccaag ccacaacccc caccggctcc agctccccag
1021 cccgtacaga gccacccacc catcatcgcg gccacccac accctgtgaa gacaaagaag
1081 ggagtgaaga ggaaagcaga caccaccacc cccaccacca ttgacccat tcacgagcca
1141 ccctcgctgc ccccgagcc caagaccacc aagctggcc agcggcggga gagcagccgg
1201 cctgtgaaac ctccaaagaa ggacgtgcc gactctcagc agcaccacg accagagaag
1261 agcagcaagg tctcggagca gctcaagtgc tgcagcggca tcctcaagga gatgttgcc
1321 aagaagcagc cgcctacgc ctggcccttc tacaagcctg tggacgtgg ggcactggc
1381 ctacacgact actgtgacat catcaagcac cccatggaca tgagcacaat caagtctaaa
1441 ctggaggccc gtgagtaccg ttagtgcctag gagtttgggt ctgacgtccg attgtatgttc
1501 tccaaactgtct ataagtacaa ccctcctgac catgagggtgg tggccatggc cgcgaagctc
1561 caggatgtgt tcgaaatgct cttgccaag atgcccggacg accctgagga gccagtgggt
1621 gccgtgtctt ccccgccagt gccccctccc accaagttt tgccccggcc ctcatccagc
1681 gacagcagca gcgatagctc ctcggacagt gacagtcga ctgatgactc tgaggaggag
1741 cgagcccgac ggctggctga gctccaggag cagctcaaag cctgtcacga gcagctgca
1801 gccctctctc agccccagca gaacaaaacca aaaaaaagg agaaaagacaa gaagaaaaaag
1861 aaaaaagaaa agcacaagaaa aaaagaggaa gtgaaagaga ataaaaaaaag caaagccaag
1921 gaacccctc ctaaaaagac gaagaaaaat aatagcagca acagcaatgt gagcaagaag
1981 gagccagcgc ccatgaagag caagccccc cccacgtatg agtcggagga agaggacaag
2041 tgcaaggccta tgccttatga ggagaagcgg cagctcagct tgacatcaa caagctcccc
2101 ggcgagaagc tggccgcgt ggtgcacatc atccagtcac gggagccctc cctgaagaat
2161 tccaaaccccg acgagattga aatcgacttt gagaccctga agccgtccac actgcgttag
2221 ctggagcgtt atgtcacctc ctgtttgcgg aagaaaagga aacctcaagc tgagaaagtt
2281 gatgtgattt cccgctcctc caagatgaag ggcttctcgt cctcagagtc ggagagctcc
2341 agttagtcca gtcctctga cagcgaagac tccgaaacag gtcctgccta atcattggac
2401 acggacttctt aataaaacgg tcttcagttt cagattccctt cccagcaagc tatagcttaa
2461 gtccatttt ttccgtgaaa gggacaggac tccatcaagt tatggaaattc ctcagagccc
2521 tggccctgtc ccccggggtt gattagtcat gtccagcagc acacgcctag tcccgccttc
2581 gggaggctg cctgcctggc cagccgccccca ggcctctctg tgtaaagact gcctggctgt
2641 cctgcccaggc cttcctgggtt ctctgggtt ctctgggtgg gtggcatctc ctggagggtg
2701 atgacaatcc ccaacacatg cattcatgtg gtgctactct gtgtgcaaaag ccagacccca
2761 agttagtttt ctctctttgt cccatccctc tttttctggg actttggacc ctaactactt
2821 ccctcctgaa cttgcagtg acatcagtc acaggagatc tcgttcagtg tgccgaaagaa
2881 cactctgacc tctagagctg tcctagataa ggagtgggag cttagaggc aaggcctcta
2941 gaccctggaa ggctcagtga ggcttctccc acagcatgtc ttcactgggt gccctgtaaag
3001 ctcgagccac cgctgactct gggctttt ggagtcttcc ctccctcgtc tccattgttc
3061 cgtgcatttc caaagcttaa gttgctgggtt ggcatttccc cagtttctat gggctccgtc
3121 ttctcaagtc acatagggaa agtacccatc

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

May 12 2004 07:05:19